TY  - JOUR
AU  - Salvador-Martin, Sara
AU  - Kaczmarczyk, Bartosz
AU  - Alvarez, Rebeca
AU  - Navas-Lopez, Victor Manuel
AU  - Gallego-Fernandez, Carmen
AU  - Moreno-Alvarez, Ana
AU  - Solar-Boga, Alfonso
AU  - Sanchez, Cesar
AU  - Tolin, Mar
AU  - Velasco, Marta
AU  - Muñoz-Codoceo, Rosana
AU  - Rodriguez-Martinez, Alejandro
AU  - Vayo, Concepcion A
AU  - Bossacoma, Ferran
AU  - Pujol-Muncunill, Gemma
AU  - Fobelo, Maria J
AU  - Millan-Jimenez, Antonio
AU  - Magallares, Lorena
AU  - Martinez-Ojinaga, Eva
AU  - Loverdos, Ines
AU  - Eizaguirre, Francisco J
AU  - Blanca-Garcia, Jose A
AU  - Clemente, Susana
AU  - Garcia-Romero, Ruth
AU  - Merino-Bohorquez, Vicente
AU  - Gonzalez-de-Caldas, Rafael
AU  - Vazquez, Enrique
AU  - Dopazo, Ana
AU  - Sanjurjo-Saez, Maria
AU  - Lopez-Fernandez, Luis A
PY  - 2021
DO  - 10.3390/pharmaceutics13010077
SN  - 1999-4923
UR  - http://hdl.handle.net/10668/16953
T2  - Pharmaceutics
AB  - Up to 30% of patients with pediatric inflammatory bowel disease (IBD) do not respond to anti-Tumor Necrosis Factor (anti-TNF) therapy. The aim of this study was to identify pharmacogenomic markers that predict early response to anti-TNF drugs in...
LA  - en
PB  - MDPI
KW  - Crohn disease
KW  - Adalimumab
KW  - Biomarker
KW  - Gene expression
KW  - Inflammatory bowel disease
KW  - Infliximab
KW  - Ulcerative colitis
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Genes
KW  - Tumor Necrosis Factor-alpha
KW  - Cohort Studies
KW  - Pharmaceutical Preparations
KW  - Biomarkers
KW  - Inflammatory Bowel Diseases
TI  - Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease.
TY  - research article
VL  - 13
ER  -